Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 221-220-5 | CAS number: 3033-62-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- The study was not performed according to any established regulatory guidelines, rather, an internal BRRC protocol. A few minor details were not described in the report, however all major report elements are present, and the study was conducted in accordance to established GLP procedures. Material balance was not established.
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 989
- Report date:
- 1989
Materials and methods
- Objective of study:
- toxicokinetics
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 417 (Toxicokinetics)
- GLP compliance:
- yes
Test material
- Reference substance name:
- N,N,N',N'-tetramethyl-2,2'-oxybis(ethylamine)
- EC Number:
- 221-220-5
- EC Name:
- N,N,N',N'-tetramethyl-2,2'-oxybis(ethylamine)
- Cas Number:
- 3033-62-3
- Molecular formula:
- C8H20N2O
- IUPAC Name:
- {2-[2-(dimethylamino)ethoxy]ethyl}dimethylamine
- Test material form:
- liquid
Constituent 1
- Specific details on test material used for the study:
- - Name of test material (as cited in study report): Bis(2-(dimethylamino)-ethyl)ether
- Physical state: liquid
- Analytical purity: 97.5-97.8%
- Specific activity (if radiolabelling): minimum of 5 uCi
- Stability under test conditions: stable
- Storage condition of test material: room temperature - no special requirements - Radiolabelling:
- yes
- Remarks:
- C14
Test animals
- Species:
- rat
- Strain:
- other: CDF® Fischer 344
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Sprague Dawley, Inc. (Indianapolis, IN)
- Age at study initiation: 11 - 12 weeks old
- Weight at study initiation: 0.232 +/- 0.010 kg (males); 0.146 +/- 0.006 kg to 0.169 +/- 0.010 kg (females)
- Fasting period before study: not applicable
- Housing: prior to use in the study, animals were housed in plastic shoe box cages in groups of 3 to 4 rats.
- Individual metabolism cages: yes - animals selected for the material balance study were transferred to individual Roth-type metabolism cages.
- Diet (e.g. ad libitum): Agway Certified Rodent Chow, St. Marys, OH, ad libitum
- Water (e.g. ad libitum): Municipal drinking water (Municipal Authority of Westmoreland County, Greensburg, PA), ad libitum
- Acclimation period: at least 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/- 3 deg C
- Humidity (%):40-70%
- Air changes (per hr): Air change ca.. every 5 minutes
- Photoperiod (hrs dark / hrs light): 12-hour photoperiod
IN-LIFE DATES: From: 1987-02-04 To: no data
Administration / exposure
- Route of administration:
- dermal
- Vehicle:
- water
- Details on exposure:
- ADMINISTRATION:
- Type of exposure: cutaneous administration (dose solution applied to a 4-6 cm2 area in the interscapular region of the back using a syringe; amount of dose delivered determined by weighing the syringe before and after delivery); application site was occluded to prevent oral ingestion and maximize skin penetration
- Target doses: dose selected was determined from kinetic information obtained via the i.v. route. - Duration and frequency of treatment / exposure:
- single dose, 48-hour exposure duration
Doses / concentrations
- Remarks:
- Doses / Concentrations:
Nominal doses: 200.0 mg/kg nominal dose level for the main and additional percutaneous studies. [Target radioactivity was 10-15 microCuries/0.2 ml of the tracer to a 200 g rat]
Actual doses reported as follows:
- Percutaneous Males: 184.0 mg/kg actual dose level with 73.6 +/- 0.24 uCi/kg radioactive dose level
- Percutaneous Female Group I: 184.0 mg/kg actual dose level with 71.275 +/- 1.59 uCi/kg radioactive dose level
- Percutaneous Female Group II: 200.0 mg/kg actual dose level with 63.275 +/- 0.88 uCi/kg radioactive dose level
- Percutaneous Male Repeat Study: 198.0 mg/kg actual dose level with 169.8 +/- 9.7 uCi/kg radioactive dose level
- Percutaneous Female Repeat Study: 205.2 mg/kg actual dose level with 318.0 +/- 15.7 uCi/kg radioactive dose level
- No. of animals per sex per dose / concentration:
- 4
- Control animals:
- no
- Details on study design:
- -Cutaneous Study Design (Pharmacokinetics and Material Balance in Rats):
This part of the investigation was conducted in separate segments for each sex. Eight rats were implanted with indwelling jugular cannulas and placed individually into Roth-type glass metabolism cages for acclimation prior to dose administration. The animals were lightly clipped in a 4-6 cm2 area in the shoulder region of the back at the dosing site. Animals were allowed between 24 and 36 hours to recover from surgery.
On the first day of the test, four rats that had patent cannulae were selected for treatment and the test substance was administered as previously described. Blood samples were collected at 0 (pre-administration), 0.5, 1, 2, 4, 6, 12, 18, 24, 36 and 48-hr post-dosing. The plasma samples were processed for LSC and analyzed for parent compound. Urine was collected in 12-hr intervals and feces in 24-hr intervals under dry ice freezing conditions and assayed for 14C. Selected urine samples were analyzed by HPLC to assess the amount of unchanged test substance eliminated by this route.
Forty-eight hours after administration of dose, the animals were killed. Skin sections from each animal (dosed site, skin around the periphery of the site, pelt) were removed. Following removal of the pelts, the liver, kidney, bone marrow, brain, fat (perirenal), heart, lung, muscle, spleen and testes/ovaries were isolated from the carcass. The dose site and peripheral skin were weighed and skin segments from two remote areas (ventral surface and sacral regions) were taken in order to examine the possibility of both radial diffusion of the test substance from the dose site and systemic distribution of the test substance to the skin. The skin sections, tissues, organs, carcass, feces, blood, and occlusive were assessed for radioactivity.
Additional studies: Pharmacokinetic experiments, the following modifications were made: blood collection times were 0.25, 0.5, 1, 2, 4, 6, 9, 12, 24, 30, 36, and 48 hr; urine samples were collected at 6, 12, 24, 36, and 48 hr, feces were collected at 24 and 48 hr; the pelt was not removed before homogenization of the carcass.
The pharmacokinetic description of the fate of 14C-test substance was evaluated using RSTRIP to derive optimum parameter estimates for the plasma data. Mean plasma 14C concentrations (microgram Equiv/g) were used to fit a two compartment open pharmacokinetic model in which elimination and transfer of l4C-test substance between compartments was assumed to be first-order processes. The parameters which were estimated included: the rate constant of absorption, ka; the rate constant of elimination, ke; and the half-lives (t1/2) of absorption and elimination. - Details on dosing and sampling:
- Dose volume: Target volume of 1.0 ml/kg, or 0.5 ml/kg (in the additional rat experiments)
Rationale for dose selection: The dose selected for the dermal administration was determined from kinetic information obtained via the intravenous LD50 preliminary study.
DOSING SOLUTION ANALYSIS: Dosing solutions were analyzed for the test substance by capillary GC with a flame ionization detector after dosing.
PHARMACOKINETIC STUDY (Absorption, distribution, excretion)
- Tissues and body fluids sampled: urine, faeces, blood, plasma, serum or other tissues, cage washes
- Time and frequency of sampling:
-- Collection of blood: Blood samples (approx. 0.1 ml) were collected via the indwelling jugular cannulae of rats at 0 (pre-administration), 0.5, 1, 2, 4, 6, 9, 12, 18, 24, 36 and 48 hours post-dosing. In the additional rat percutaneous pharmacokinetic experiments, the following modifications were made: blood collection times were 0.25, 0.5, 1, 2, 4, 6, 9, 12, 24, 30, 36 and 48 hr.
-- Collection of urine and faeces: Urine and feces were collected in 12-hr intervals. In the additional rat percutaneous pharmacokinetic experiments, the following modifications were made: urine samples were collected at 6, 12, 24, 36 and 48 hr, feces were collected at 24 and 48 hr.
-- Collection of expired air: In the additional rat percutaneous pharmacokinetic experiments, the following modifications were made: CO2 trapping
solutions and volatile traps were collected at 24 and 48 hr.
-- Analysis of organs: Following removal of the pelts the liver, kidney, bone marrow, brain, fat (perirenal), heart, lung, muscle, spleen and tested ovaries were isolated from the carcass.
SAMPLE PREPARATION
- Storage procedure: Blood was collected in heparinized capillary tubes. Urine and feces were collected under dry ice conditions and the urine samples were frozen at approximately -80 deg C until the preliminary metabolite analysis was conducted.
- Preparation details:
-- Blood: The blood collected was placed in heparinized capillary tubes and plasma prepared. An aliquot of the plasma was added to 10 ml of Aquasol-2(R) counting scintillant and counted by liquid scintillation spectrometry. Based on radioactivity levels observed, selected samples of the remaining plasma were then analyzed for metabolites and parent chemical.
-- Expired air: Forty-eight hours after administration of dose, the animals were anesthetized with methoxyflurane (rats).
-- Skin: Skin sections from each animal were removed in the following manner. The dosed area of skin, as well as the skin around the periphery of this site, were separated from each animal using blunt dissection techniques. The pelts were removed from the carcass prior to removal of organs. The dose site and peripheral skin were weighed and skin segments from two remote areas (ventral surface and sacral regions) were taken in order to examine the possibility of both radial diffusion of the test substance from the dose site and systemic distribution of test substance to the skin. The skin from both the dose site and directly surrounding it (approximately 1 cm from edge of dose site) were pulverized at liquid nitrogen temperatures in a Spex Freezer Mill and an aliquot from each sample was counted directly in a suspension of 10 ml Aquasol-2QD and 6 ml water. In the additional rat percutaneous pharmacokinetic experiments, the following modifications were made: the pelt was not removed before homogenization of the carcass.
ANALYSIS
- Method type(s) for identification: Liquid scintillation counting. Radioactivity was determined by tissue oxidation of isolated organs, and tissues, aliquots of homogenized carcass and feces (33% w/v in distilled water), and red blood cells from all collection intervals. Radioactivity recovered from the dose site and from the occlusive bandage was also quantified. Tissue oxidation was conducted in a Biological Materials Oxidizer and 14CO2 derived from combustion of these tissues was quantified by liquid scintillation spectrometry.
Results and discussion
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- Percutaneous Route Pharmacokinetics: The absorption rate constant was significantly greater for males than for females. The cutaneous bioavailability of the test substance was calculated to be 78.2% in males and 50.8% in females.
- Details on distribution in tissues:
- Initial Experiment:
- Small amounts of the dose were recovered in the residual carcass, while 6.4 and 8.0% recoveries were observed in organs selected for analysis in males and females, respectively.
Additional Experiment:
- Approximately 10% was recovered in the residual carcass and the dosed skin/occlusive devices. Minor amounts of the dose were recovered in the tissues collected at necropsy; there was a modest apparent accumulation of radiolabel in several tissues relative to plasma, including lung, kidney and bone marrow.
- Details on excretion:
- Initial Experiment:
- Percutaneous Route Pharmacokinetics: The major fraction of the excreted dose was found in the urine, accounting for 24% of the dose (approximately 95% of the excreted dose). Approximately 1 to 2% of the dose (ca. 5% of the excreted dose) was recovered in the feces of male and female rats. There was no remarkable tissue specific accumulation in male or female rats. The relatively high recovery of radioactivity from the pelt suggests that the dose solution was not completely contained by the dose occlusion devices.
Additional Experiment:
- Approximately 50% of the dose was recovered in the urine and cage wash in both sexes. Minor amounts of the dose were recovered in the feces, expired CO2 and organic volatiles.
Toxicokinetic parametersopen allclose all
- Test no.:
- #1
- Toxicokinetic parameters:
- other: Ka (male) = 0.02621/min / Ka (female) = 0.008504/min
- Test no.:
- #1
- Toxicokinetic parameters:
- half-life 1st: half-life of absorption (male) = 26.45 min / half-life of absorption (female) = 81.51 min
- Test no.:
- #1
- Toxicokinetic parameters:
- other: Ke (male) = 0.0003976/min / Ke (female) = 0.000367/min
- Test no.:
- #1
- Toxicokinetic parameters:
- half-life 2nd: half-life of elimination (male) = 1744 min / half-life of elimination (female) = 1888 min
- Test no.:
- #1
- Toxicokinetic parameters:
- Cmax: Cmax (male) = 12.86 ug/g / Cmax (female) = 5.511 ug/g
- Test no.:
- #1
- Toxicokinetic parameters:
- Tmax: tmax (male) = 117.1 min / tmax (female) = 238.9 min
- Test no.:
- #1
- Toxicokinetic parameters:
- AUC: AUC through 48 hrs (male) = 13866 ug/g*min / AUC through 48 hrs (female) = 8426 ug/g*min
- Test no.:
- #1
- Toxicokinetic parameters:
- AUC: AUC to infinite time (male) = 19220 ug/g*min / AUC to infinite time (female) = 12484 ug/g*min
- Test no.:
- #2
- Toxicokinetic parameters:
- other: Ka (male) = 6.393/hr Ka (female) = 4.945/hr
- Test no.:
- #2
- Toxicokinetic parameters:
- half-life 1st: half-life of absorption (male) = 0.1084 hr / half-life of absorption (female) = 0.1402 hr
- Test no.:
- #2
- Toxicokinetic parameters:
- other: Kd (male) = 6.225/hr Kd (female) = 4.550/hr
- Test no.:
- #2
- Toxicokinetic parameters:
- half-life 2nd: half-life of distribution (male) = 0.1114 hr / half-life of distribution (female) = 0.1524 hr
- Test no.:
- #2
- Toxicokinetic parameters:
- other: Ke (male) = 0.0300/hr Ke (female) = 0.0382/hr
- Test no.:
- #2
- Toxicokinetic parameters:
- half-life 3rd: half-life of elimination (male) = 23.10 hr / half-life of elimination (female) = 18.145 hr
- Test no.:
- #2
- Toxicokinetic parameters:
- Cmax: Cmax (male) = 86.83 ug/g / Cmax (female) = 175.7 ug/g
- Test no.:
- #2
- Toxicokinetic parameters:
- Tmax: Tmax (male) = 0.1650 hr / Tmax (female) = 0.2197 hr
- Test no.:
- #2
- Toxicokinetic parameters:
- AUC: AUC through 48 hrs (male) = 266.1 ug/g*hr / AUC through 48 hrs (female) = 338.4 ug/g*hr
- Test no.:
- #2
- Toxicokinetic parameters:
- AUC: AUC to infinite time (male) = 338.3 ug/g*hr / AUC to infinite time (female) = 383.6 ug/g*hr
- Test no.:
- #2
- Toxicokinetic parameters:
- other: Bioavailability (male) = 82.55% / Bioavailability (female) = 93.60%
Metabolite characterisation studies
- Metabolites identified:
- no
- Details on metabolites:
- Percutaneous Route Pharmacokinetics: While no evidence of metabolism was observed (no metabolites seen in urine), attempts to accurately measure plasma concentrations of the test substance were unsuccessful and large fractions of the dose were not recovered. The time courses of plasma 14C concentrations showed a similar elimination phase in both sexes, but males showed generally higher plasma concentrations.
In the initial HPLC analyses of urine samples, there was no indication of urinary metabolites; however, in the additional rat percutaneous experiments, a second component, possibly a metabolite of the test substance, accounted for a maximum of approximately 10% of the total urinary radioactivity.
Any other information on results incl. tables
Relatively large amounts of the dose were associated with the dosing site and occlusion devices in both males and females. However, large fractions of the dose (51.8% in males and 39.3% in females) could not be accounted for (see Table 1).
Table 1: Disposition of Radioactivity Following Cutaneous Administration of 200 mg/kg to Fischer 344 Rats - Initial Experiment
% Recovery - Males | % Recovery - Females | |
A. Tissues & Excreta | ||
Collected Blood | 0.034 +/- 0.015 | 0.025 +/- 0.010 |
Urine (0 - 24 hr) | 12.376 +/- 3.892 | 12.176 +/- 5.110 |
Urine (24 - 48 hr) | 4.767 +/- 1.711 | 7.452 +/- 2.169 |
Cage Wash | 6.394 +/- 2.825 | 4.209 +/- 2.116 |
Subtotals | 23.537 +/- 1.787 | 23.837 +/- 3.915 |
Feces (0 - 24 hr) | 1.506 +/- 2.407 | 0.944 +/- 0.968 |
Feces (24 - 48 hr) | 0.246 +/- 0.145 | 0.062 +/- 0.074 |
Subtotals | 1.752 +/- 2.511 | 1.006 +/- 0.900 |
Tissues | 6.399 +/- 1.035 | 8.029 +/- 2.880 |
Carcass | 1.916 +/- 0.188 | 2.163 +/- 0.327 |
Section A Totals | 33.639 +/- 2.513 | 35.061 +/- 5.350 |
B. Occlusion Devices and Skin | ||
Tape, jacket & plastic rinses | 11.570 +/- 2.618 | 20.931 +/- 5.485 |
Combustion of plastic | 0.008 +/- 0.003 | 0.006 +/- 0.001 |
Skin rinses | 0.392 +/- 0.106 | 0.192 +/- 0.131 |
Recovery in skin | 2.534 +/- 0.440 | 4.558 +/- 2.200 |
Section B Totals | 14.504 +/- 2.825 | 25.688 +/- 7.560 |
Total % Recovered Dose | 48.142 +/- 5.003 | 60.749 +/- 12.042 |
- Additional studies: Additional percutaneous pharmacokinetic experiments were conducted in four male and three female (one of the original four animals died during the study of unknown causes). The total recovery of the dose was approximately 75 to 80% (see Table 2), which, while markedly higher than in the initial experiment, is relatively low. The cause of the reduced recoveries is unknown.
Table 2: Disposition of Radioactivity Following Cutaneous Administration of 200 mg/kg to Fischer 344 Rats - Additional Experiment
% Recovery - Males | % Recovery - Females | |
A. Tissues & Excreta | ||
Collected Blood | 0.076 +/- 0.045 | 0.250 +/- 0.294 |
Urine (0 - 12 hr) | 21.464 +/- 4.292 | 16.021 +/- 5.932 |
Urine (12 - 24 hr) | 12.480 +/- 2.683 | 8.149 +/- 1.501 |
Urine (24 - 48 hr) | 12.712 +/- 5.585 | 11.231 +/- 4.478 |
Cage Wash | 5.533 +/- 2.356 | 11.240 +/- 5.687 |
Subtotals | 52.189 +/- 3.407 | 46.641 +/- 2.518 |
Feces (0 - 24 hr) | 0.282 +/- 0.131 | 1.404 +/- 0.529 |
Feces (24 - 48 hr) | 0.224 +/- 0.222 | 0.529 +/- 0.244 |
Subtotals | 0.506 +/- 0.342 | 1.933 +/- 0.698 |
Expired 14CO2 (0 - 24 hr) | 0.368 +/- 0.029 | 0.244 +/- 0.039 |
Expired 14CO2 (24 - 48 hr) | 0.177 +/- 0.051 | 0.092 +/- 0.008 |
Subtotals | 0.545 +/- 0.070 | 0.336 +/- 0.046 |
Volatiles (0 - 48 hr) | 3.763 +/- 0.125 | 1.954 +/- 0.370 |
Tissues | 0.907 +/- 0.204 | 0.882 +/- 0.126 |
Carcass | 11.438 +/- 1.560 | 10.869 +/- 2.211 |
Section A Totals | 69.424 +/- 2.907 | 62.866 +/- 0.538 |
B. Occlusion Devices and Skin | ||
Tape, jacket & plastic rinses | 6.846 +/- 1.358 | 9.396 +/- 0.426 |
Combustion of plastic | 0.003 +/- 0.001 | 0.006 +/- 0.004 |
Skin rinses | 0.281 +/- 0.106 | 0.176 +/- 0.065 |
Recovery in skin | 2.881 +/- 0.572 | 3.127 +/- 0.288 |
Section B Totals | 10.011 +/- 1.825 | 12.705 +/- 0.153 |
Total % Recovered Dose | 79.435 +/- 2.769 | 75.571 +/- 0.432 |
The distribution of 14C to selected tissues (see Table 3) indicated that no remarkable tissue-specific accumulation occurred in male or female rats. The relatively high recovery of radioactivity from the pelt suggests that the dose solution was not completely contained by the dose occlusion devices.
Table 3 Distribution of Radioactivity in Tissues from Fischer 344 Rats Following Cutaneous Exposure - Initial Experiment
Male | Female | |||
Tissue | % of Dose | µg Equiv /g | % of Dose | µg Equiv /g |
Liver | 0.307 +/- 0.048 | 15.388 +/- 1.507 | 0.388 +/- 0.041 | 18.917 +/- 1.512 |
Kidney | 0.189 +/- 0.059 | 46.004 +/- 10.577 | 0.214 +/- 0.020 | 47.448 +/- 5.386 |
Bone Marrow | ---a | 61.831 +/- 17.800 | ---a | 70.755 +/- 15.091 |
Spleen | 0.045 +/- 0.016 | 17.967 +/- 5.017 | 0.067 +/- 0.007 | 26.403 +/- 2.700 |
Brain | 0.040 +/- 0.009 | 9.667 +/- 1.988 | 0.040 +/- 0.012 | 7.236 +/- 2.684 |
Heart | 0.007 +/- 0.001 | 4.098 +/- 0.654 | 0.010 +/- 0.003 | 4.929 +/- 0.891 |
Lung | 0.048 +/- 0.026 | 19.472 +/- 7.760 | 0.077 +/- 0.024 | 21.902 +/- 10.127 |
Muscle | ---a | 4.062 +/- 1.796 | ---a | 4.324 +/- 0.930 |
Skin (Pelt) | 5.673 +/- 0.997 | 74.735 +/- 13.191 | 7.212 +/- 2.850 | 84.757 +/- 31.756 |
Fat | ---a | 2.180 +/- 2.683 | ---a | 0.651 +/- 0.756 |
Ovaries | --- | --- | 0.003 +/- 0.001 | 9.285 +/- 2.727 |
Uterus | --- | --- | 0.009 +/- 0.004 | 8.483 +/- 3.483 |
Testes | 0.084 +/- 0.025 | 15.036 +/- 3.383 | --- | --- |
a Percent of dose not expressed since tissue was only partially sampled (entire tissue not collectable).
In the Additional Experiment,minor amounts of the dose were recovered in the tissues collected at necropsy (see Table 4). There was a modest apparent accumulation of radiolabel in several tissues relative to plasma, including lung, kidney and bone marrow.
Table 4. Distribution of Radioactivity in Tissues from Fischer 344 Rats Following Cutaneous Exposure - Additional Experiment
Tissue | Male | Female | ||
% of Dose | µg Equiv /g | % of Dose | µg Equiv /g | |
Plasma | 0.008 +/- 0.002b | 1.549 +/- 0.228 | 0.006 +/- 0.000b | 1.356 +/- 0.106 |
Liver | 0.438 +/- 0.088 | 23.899 +/- 2.737 | 0.397 +/- 0.053 | 21.194 +/- 1.365 |
Kidney | 0.195 +/- 0.052 | 51.335 +/- 11.720 | 0.222 +/- 0.040 | 52.985 +/- 9.150 |
Bone Marrow | 0.007 +/- 0.001b | 98.051 +/- 14.361 | 0.009 +/- 0.001b | 91.393 +/- 9.411 |
Spleen | 0.046 +/- 0.013 | 25.757 +/- 7.149 | 0.038 +/- 0.025 | 16.937 +/- 10.609 |
Brain | 0.041 +/- 0.004 | 10.655 +/- 1.577 | 0.055 +/- 0.010 | 10.406 +/- 0.276 |
Heart | 0.011 +/- 0.002 | 7.056 +/- 1.311 | 0.025 +/- 0.021 | 13.234 +/- 11.279 |
Lung | 0.084 +/- 0.037 | 35.837 +/- 13.805 | 0.120 +/- 0.030 | 40.637 +/- 9.065 |
Muscle | 0.005 +/- 0.001b | 6.756 +/- 1.896 | 0.006 +/- 0.000b | 6.718 +/- 0.891 |
Fat | 0.000 +/- 0.000b | 1.709 +/- 0.488 | 0.001 +/- 0.000b | 1.472 +/- 0.429 |
Ovaries | --- | --- | 0.003 +/- 0.000 | 10.184 +/- 0.611 |
Uterus | --- | --- | 0.007 +/- 0.002 | 10.373 +/- 0.621 |
Testes | 0.080 +/- 0.011 | 14.058 +/- 2.177 | --- | --- |
a Means were computed from groups of four males and three females.
b Percent of dose expressed for sample assayed but tissue was only partially sampled (entire tissue not collectable).
The
time courses of plasma 14C concentrations following cutaneous
exposures in male and female rats show that absorption and distribution
of the test substance were very rapid in both sexes. The
estimated maximal 14C plasma concentration was reached within
0.25 hr, while the distribution phase was apparently complete by 2 to 4
hr. Elimination
of 14C was moderately slow in both sexes although it appeared
to occur slightly more rapidly in females. The
calculated percutaneous bioavailability was greater than 80% in both
sexes.
The major differences in the outcomes of the initial and additional
percutaneous rat studies are: 1) a greater fraction of the dose was
recovered in the additional studies, with greater recovery in the urine
and less in the dose skin/occlusion devices; 2) the absorption half-life
and time to Cmax were much shorter in the additonal studies and the
half-life of elimination was decreased; 3) the apparent percutaneous
bioavailability was higher in the additional studies, particularly in
females.
Applicant's summary and conclusion
- Conclusions:
- Pharmacokinetic profile is consistent with a two-compartment open model in which elimination is primarily by urine excretion of the unchanged test material. Metabolism is not a major feature of Bis(2-(dimethylamino)-ethyl)ether elimination.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.